Buy Delagil pills 250 mg, 30 pcs
  • Buy Delagil pills 250 mg, 30 pcs

Delagil® [Chloroquine]

Meda Pharma GmbH & Co. KG
Dosage form
Brand & Manufacturer
Package Size
$22.25
Quantity
There are not enough products in stock
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

The antiprotozoal agent also has an immunosuppressive and anti-inflammatory effect. Delagil causes the death of asexual erythrocyte forms of all types of plasmodia. It has a gametocidal effect, with the exception of Plasmodium falciparum (exhibits anti-gametocidal action).

Indications

Malaria (prevention and treatment of all types), extraintestinal amebiasis, amebic liver abscess, systemic lupus erythematosus (SLE) (chronic and subacute forms), rheumatoid arthritis, scleroderma, photodermatosis.

Composition

1 tablet contains chloroquine 250 mg

No customer reviews for the moment.

Write your review

Write your review

Delagil® [Chloroquine]

Dosage and Administration

Delagil is taken orally, after meals.
In the treatment of malaria prescribed 2-2.75 g per course of treatment: 1 g / first day, after 11-12 hours 0.5 g, on the second and third day - 0.5-0.75 g at one time. The maximum dosage for adults is 1.5 g at a time. Children 6-10 years prescribed 0.25 g in the first day, then 0.125 g in the second and third days of treatment. Children 10-15 years old - 0.5 g / first day, then 0.25 g each on the second and third day.
Prevention of malaria infection: 0.5 g twice a week, then 0.5 g once a week. In the case of rheumatoid arthritis, Delagil is taken at a rate of 0.5 g / day for 2 doses for 6–8 days. Then daily 0.25 g for 12 months.

Adverse reactions

- Of the nervous system: dizziness, psychomotor agitation, headache, insomnia, psychosis, neuropathy, seizures.
- From the side of the musculoskeletal system: myopathy.
- On the part of sensitive analyzers: hearing loss, tinnitus, impaired visual perception, corneal clouding, retinopathy, accommodation disturbance, reversible keratopathy.
- On the part of the digestive system: nausea, vomiting, diarrhea, anorexia, abdominal pain of a spastic nature, weight loss, hepatotoxicity.
- From the side of vascular system: development of arterial hypotension, cardiomyopathy is possible.
- Skin manifestations: dermatitis, pruritus, rash, photosensitivity, impaired skin pigmentation, hair loss.

Contraindications

Renal and hepatic failure, severe cardiac arrhythmias, oppression of blood formation in the bone marrow, porphyrinuria, neutropenia, hypersensitivity to the constituent components of the drug, children under 6 years of age.

Drug interactions

The combined use of other antimalarial drugs enhances the action of Delagil. Can not be taken in conjunction with gold medications, cytostatics, penicillamine, levamisole, because This may increase the side effects of the drug. When used together with MAO inhibitors, the toxic effect is enhanced. With long-term use of Delagil together with cardiac glycosides may develop glycoside intoxication. Ethanol enhances the toxic effect of Delagil on the liver.

Overdosage

Overdose of this drug causes loss of consciousness, vomiting, respiratory depression, seizures, collapse. In case of overdose, it is necessary to flush the stomach, take the adsorbents inside. In severe cases of poisoning, plasmapheresis and peritoneal dialysis are possible.

  • Brand name: Delagil
  • Active ingredient: Chloroquine
  • Dosage form: pills
  • Manufacturer: Meda Pharma GmbH & Co. KG
  • Country of Origin: Switzerland

Studies and clinical trials of Chloroquine (Click to expand)

  1. Effect of chloroquine-induced myopathy on rat soleus muscle sarcoplasm and expression of clathrin
  2. Familial interstitial lung disease in children: Response to chloroquine treatment in one sibling with desquamative interstitial pneumonitis
  3. No effect of chloroquine on theophylline pharmacokinetics in the rat
  4. Polyamine metabolism in various tissues during pathogenesis of chloroquine-susceptible and resistant malaria
  5. Preparation of 198Au(I)-labelled gold-chloroquine complex [198Au(PPh3)(CQ)]PF6 as a potential antimalarial agent
  6. Diagnosis of a case of acute chloroquine poisoning using 1H NMR spectroscopy: characterisation of drug metabolites in urine
  7. Synthesis and optical properties of the chloroquine enantiomers and their complexes with ferriprotoporphyrin IX in aqueous solution
  8. Studies on the role of proteases in the white-rot fungus Trametes versicolor: Effect of PMSF and chloroquine on ligninolytic enzymes activity
  9. Enhancement of the radiation response of cultured tumor cells by chloroquine
  10. In vitro activity of chloroquine and quinine in combination with desferrioxamine against Plasmodium falciparum
  11. Soluble Synthetic Analogues of Malaria Pigment: Structure of Mesohematin Anhydride and its Interaction with Chloroquine in Solution
  12. Titelbild: Soluble Synthetic Analogues of Malaria Pigment: Structure of Mesohematin Anhydride and its Interaction with Chloroquine in Solution (Angew. Chem. 27/2011)
  13. Soluble Synthetic Analogues of Malaria Pigment: Structure of Mesohematin Anhydride and its Interaction with Chloroquine in Solution
  14. Cover Picture: Soluble Synthetic Analogues of Malaria Pigment: Structure of Mesohematin Anhydride and its Interaction with Chloroquine in Solution (Angew. Chem. Int. Ed. 27/2011)
  15. From Chloroquine to Antineoplastic Drugs? The Story of Antibacterial Quinolones
  16. A controlled study of chloroquine as an antirheumatic agent
  17. Chloroquine and hydroxychloroyuine therapy in rheumatoid arthritis
  18. A double-blind comparison of the anti-rheumatic properties of amopyroquin-HCl (Propoquin) and chloroquine-diphosphate
  19. Effect of chloroquine on the sulfhydryl group and the denaturation of bovine serum albumin
  20. Diplopia and loss of accommodation due to chloroquine
  21. An appraisal of chloroquine
  22. Prevention by chloroquine of hexosamine cartilage depletion by e-prostaglandins
  23. Chloroquine inhibits the production of a mononuclear cell factor by inhibition of lectin binding
  24. A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis

7 other products in the same category:

arrow_upward